MMP14 and glioblastoma: In conclusion, we established the feasibility of the use of MT1-MMP-based immunoPET for an efficient detection of GBM and it opens the possibility of using engineered anti-MT1-MMP mAbs to more accurate biological characterization and diagnosis of GBM, as an alternate to non-specific tracers.